Document is current
Any future updates will be listed below
-
Authors
Kuemmerle, Louis B. https://orcid.org/0000-0002-9193-1243
Luecken, Malte D. https://orcid.org/0000-0001-7464-7921
Firsova, Alexandra B.
Barros de Andrade e Sousa, Lisa
Straßer, Lena
Mekki, Ilhem Isra
Campi, Francesco
Heumos, Lukas
Shulman, Maiia https://orcid.org/0009-0006-6308-1997
Beliaeva, Valentina
Hediyeh-Zadeh, Soroor https://orcid.org/0000-0001-7513-6779
Schaar, Anna C.
Mahbubani, Krishnaa T. https://orcid.org/0000-0002-1327-2334
Sountoulidis, Alexandros https://orcid.org/0000-0002-8837-4642
Balassa, Tamás
Kovacs, Ferenc https://orcid.org/0000-0003-4512-4448
Horvath, Peter
Piraud, Marie
Ertürk, Ali https://orcid.org/0000-0001-5163-5100
Samakovlis, Christos
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
-
Funding
Funding for this research was provided by:
Helmholtz Association (KA1-Co-02 “COVIPA”)
EC | Horizon 2020 Framework Programme (874656, 874656)
- License Information
-
More Information
Article History
Received: 19 July 2022
Accepted: 30 September 2024
First Online: 18 November 2024
Competing interests
: F.J.T. consults for Immunai Inc., CytoReason Ltd, Cellarity and BioTuring Inc., and has an ownership interest in Dermagnostix GmbH and Cellarity. M.D.L. contracted for the Chan Zuckerberg Initiative and received speaker fees from Pfizer and Janssen Pharmaceuticals. P.H., F.K. and T.B. acknowledge support from TKP2021-EGA09, Horizon-BIALYMPH, -SYMMETRY, -SWEEPICS, -Fair-CHARM and OTKA-SNN 139455.
